top of page
Search
Biologics R&D: select news
A protective and broadly binding antibody class engages the influenza virus hemagglutinin head at its stem interface
https://pubmed.ncbi.nlm.nih.gov/40391889/
jeanfrancoismaison
May 211 min read
Ā
Ā
Ā
Association between herpes simplex virus type 1 and the risk of Alzheimer's disease: a retrospective case-control study
https://pubmed.ncbi.nlm.nih.gov/40393802/
jeanfrancoismaison
May 211 min read
Ā
Ā
Ā
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
https://pubmed.ncbi.nlm.nih.gov/40395132/
jeanfrancoismaison
May 211 min read
Ā
Ā
Ā
Heterogeneity in recombination rates and accessory gene co-occurrence distinguish Pseudomonas aeruginosa phylogroups
https://pubmed.ncbi.nlm.nih.gov/40304385/
jeanfrancoismaison
May 211 min read
Ā
Ā
Ā
m276-SL-PBD eradicates tumors and instigates long-lasting tumor-free survival in Merkel cell carcinoma preclinical models
https://pubmed.ncbi.nlm.nih.gov/40384933/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
The CD70-CD27 axis in cancer immunotherapy: Predictive biomarker and therapeutic target
https://pubmed.ncbi.nlm.nih.gov/40388162/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
Safety and efficacy of antigen-specific therapeutic approaches for multiple sclerosis: Systematic review
https://pubmed.ncbi.nlm.nih.gov/40388453/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development
https://pubmed.ncbi.nlm.nih.gov/39953671/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis
https://pubmed.ncbi.nlm.nih.gov/40357526/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
A Self-Assembling Cross-Protective Antigen Against Multiple Gram-Positive Nosocomial Pathogens
https://pubmed.ncbi.nlm.nih.gov/40385225/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
Virus-like particles: a versatile and effective vaccine platform
https://pubmed.ncbi.nlm.nih.gov/40387310/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: A two-year follow-up study
https://pubmed.ncbi.nlm.nih.gov/40388467/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
Shared neoantigens' atlas for off-the-shelf cancer vaccine development
https://pubmed.ncbi.nlm.nih.gov/40390041/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
Emerging New Treatments for Colon Cancer
https://pubmed.ncbi.nlm.nih.gov/40390224/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
An update on the clinical trial research of immunotherapy for glioblastoma
https://pubmed.ncbi.nlm.nih.gov/40386781/
jeanfrancoismaison
May 201 min read
Ā
Ā
Ā
Botulinum neurotoxins exploit host digestive proteases to boost their oral toxicity via activating OrfXs/P47
https://pubmed.ncbi.nlm.nih.gov/39838108/
jeanfrancoismaison
May 191 min read
Ā
Ā
Ā
An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19
https://pubmed.ncbi.nlm.nih.gov/40245494/
jeanfrancoismaison
May 191 min read
Ā
Ā
Ā
Impact of age and prior COVID-19 on the response to influenza a components in the 2020-2021 Fluzone vaccine
https://pubmed.ncbi.nlm.nih.gov/40328185/
jeanfrancoismaison
May 191 min read
Ā
Ā
Ā
Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (IndovacĀ®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled st
https://pubmed.ncbi.nlm.nih.gov/40381203/
jeanfrancoismaison
May 191 min read
Ā
Ā
Ā
Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants
https://pubmed.ncbi.nlm.nih.gov/40383081/
jeanfrancoismaison
May 191 min read
Ā
Ā
Ā
bottom of page